Related references
Note: Only part of the references are listed.Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF).
Ruben A. Mesa et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
Vikas Gupta et al.
HAEMATOLOGICA (2017)
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
John O. Mascarenhas et al.
HAEMATOLOGICA (2017)
A phase I, open-label, dose-escalation, multicenter study of the JAK2 inhibitor NS-018 in patients with myelofibrosis
S. Verstovsek et al.
LEUKEMIA (2017)
A phase 1/2, open-label study evaluating twice-daily administration of momelotinib in myelofibrosis
Vikas Gupta et al.
HAEMATOLOGICA (2017)
Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis
John O. Mascarenhas et al.
HAEMATOLOGICA (2017)
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
Srdan Verstovsek et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis (vol 30, pg 1701, 2016)
C. N. Harrison et al.
LEUKEMIA (2017)
The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1
Andrew A. Wylie et al.
NATURE (2017)
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
Peter C. Taylor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents
Malte Asshoff et al.
BLOOD (2017)
Somatic JAK2 mutations and their tumor phenotypes
Ayalew Tefferi
BLOOD (2016)
Cotargeting BCL-2 and BCL-XL for maximal efficacy in ALL
Naval Daver et al.
BLOOD (2016)
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
Vikas Gupta et al.
HAEMATOLOGICA (2016)
Ruxolitinib dose management as a key to long-term treatment success
Ruben A. Mesa et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)
Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies
Srdan Verstovsek et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Baricitinib in Patients with Refractory Rheumatoid Arthritis
Mark C. Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation
Shannon Elf et al.
CANCER DISCOVERY (2016)
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
Vikas Gupta et al.
HAEMATOLOGICA (2016)
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
Keyur P. Patel et al.
BLOOD (2015)
Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis
Rami S. Komrokji et al.
BLOOD (2015)
The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis
Michael Deininger et al.
BLOOD (2015)
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms
Sara C. Meyer et al.
CANCER CELL (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis
Elizabeth O. Hexner et al.
LEUKEMIA & LYMPHOMA (2015)
A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis
Srdan Verstovsek et al.
LEUKEMIA RESEARCH (2015)
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis
P. Guglielmelli et al.
BLOOD CANCER JOURNAL (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis A Randomized Clinical Trial
Animesh Pardanani et al.
JAMA ONCOLOGY (2015)
RAP-011, an activin receptor ligand trap, increases hemoglobin concentration in hepcidin transgenic mice
Jacqueline M. Langdon et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis
Ramy A. Abdelrahman et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis
A. Pardananil et al.
LEUKEMIA (2015)
Does anything work for anaemia in myelofibrosis?
Gunnar Birgegard
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2014)
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
Elisa Rumi et al.
BLOOD (2014)
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms
Neha Bhagwat et al.
BLOOD (2014)
Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study
Paola Guglielmelli et al.
BLOOD (2014)
Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
Raajit Rampal et al.
BLOOD (2014)
Molecular Pathways: Molecular Basis for Sensitivity and Resistance to JAK Kinase Inhibitors
Sara C. Meyer et al.
CLINICAL CANCER RESEARCH (2014)
The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis
Juan-Carlos Hernandez-Boluda et al.
HAEMATOLOGICA (2014)
Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?
G. Barosi et al.
LEUKEMIA (2014)
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients
A. Tefferi et al.
LEUKEMIA (2014)
CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
A. Tefferi et al.
LEUKEMIA (2014)
Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact
A. Tefferi et al.
LEUKEMIA (2014)
Epidemiology of myeloproliferative neoplasms in the United States
Jyotsna Mehta et al.
LEUKEMIA & LYMPHOMA (2014)
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
Srdan Verstovsek et al.
LEUKEMIA RESEARCH (2014)
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis
Y. Nakaya et al.
BLOOD CANCER JOURNAL (2014)
The Janus Kinase 2 Inhibitor Fedratinib Inhibits Thiamine Uptake: A Putative Mechanism for the Onset of Wernicke's Encephalopathy
Qiang Zhang et al.
DRUG METABOLISM AND DISPOSITION (2014)
Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis
Animesh Pardanani et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
Ayalew Tefferi et al.
BLOOD (2013)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis
John Mascarenhas et al.
BLOOD (2013)
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
Srdan Verstovsek et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
Ruben A. Mesa et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
A. Pardanani et al.
LEUKEMIA (2013)
Mutations and prognosis in primary myelofibrosis
A. M. Vannucchi et al.
LEUKEMIA (2013)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
Thorsten Klampfl et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Improving Survival Trends in Primary Myelofibrosis: An International Study
Francisco Cervantes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
Robyn M. Emanuel et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition
Oliver Weigert et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
Priya Koppikar et al.
NATURE (2012)
Challenges Facing JAK Inhibitor Therapy for Myeloproliferative Neoplasms
Ayalew Tefferi
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent
Rita Andraos et al.
CANCER DISCOVERY (2012)
Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms
Shubha Anand et al.
BLOOD (2011)
Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Animesh Pardanani et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
What are RBC-transfusion-dependence and -independence?
R. P. Gale et al.
LEUKEMIA RESEARCH (2011)
Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms
Y. Nakaya et al.
BLOOD CANCER JOURNAL (2011)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
Jeffrey W. Tyner et al.
BLOOD (2010)
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans
Sachie Marubayashi et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis.
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Constantine S. Tam et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients
A. Pardanani et al.
LEUKEMIA (2009)
The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
Ruben A. Mesa et al.
LEUKEMIA RESEARCH (2009)
Leptin protects against 6-hydroxydopamine-induced dopaminergic cell death via mitogen-activated protein kinase signaling
Zhongfang Weng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
MPL515 mutations in myeloproliferative and other myeloid disorders:: a study of 1182 patients
Animesh D. Pardanani et al.
BLOOD (2006)
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
Ayalew Tefferi et al.
BLOOD (2006)
MPLW515L is anovel somatic activating mutation in myelofibrosis with myeloid metaplasia
Yana Pikman et al.
PLOS MEDICINE (2006)
Erythropoietin promotes regeneration of adult CNS neurons via Jak2/Stat3 and PI3K/Akt pathway activation
A Kretz et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Medical progress: Myelofibrosis with myeloid metaplasia.
A Tefferi
NEW ENGLAND JOURNAL OF MEDICINE (2000)